Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Schrödinger Inc.’s stock soared 9% early Tuesday, after the company said it has entered a multi-year collaboration agreement ...

Novartis (NVS) has been beaten down lately with too much selling pressure. While the stock has lost 9.7% over the past four ...

Following their declassification, the former protected witnesses are now facing the political figures they had named as ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...

Schrodinger, Inc. (NASDAQ:SDGR) shares are trading higher on Tuesday. The company disclosed a research collaboration and ...

Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...

Janus Henderson, Coastal Financial, Novartis, Apogee and InterDigital have been highlighted in this Screen of The Week ...

UBS analyst Matthew Weston maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF111.00. According to TipRanks, Weston is ranked #1736 out of 9162 analysts ...